Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state.

Inherited mutations in the erythropoietin receptor (EPOR) causing premature termination of the receptor cytoplasmic region are associated with dominant familial erythrocytosis (FE), a benign clinical condition characterized by hypersensitivity of erythroid progenitor cells to EPO and low serum EPO (S-EPO) levels. We describe a Swedish family with dominant FE in which erythrocytosis segregates with a new truncation in the negative control domain of the EPOR. We show that cells engineered to concomitantly express the wild-type (WT) EPOR and mutant EPORs associated with FE (FE EPORs) are hypersensitive to EPO-stimulated proliferation and activation of Jak2 and Stat5. These results demonstrate that FE is caused by hyperresponsiveness of receptor-mediated signaling pathways and that this is dominant with respect to WT EPOR signaling.

[1]  M. Goldsmith,et al.  Oligomerization and Scaffolding Functions of the Erythropoietin Receptor Cytoplasmic Tail* , 1999, The Journal of Biological Chemistry.

[2]  R. Kralovics,et al.  Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. , 1997, Blood.

[3]  M. Arcasoy,et al.  Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. , 1997, Blood.

[4]  A. Yoshimura,et al.  CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. , 1997, Blood.

[5]  B. Groner,et al.  Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. , 1996, The EMBO journal.

[6]  J. Krosl,et al.  Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin‐induced cell proliferation and Stat5 activation. , 1995, The EMBO journal.

[7]  G. Semenza,et al.  Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. , 1995, Blood.

[8]  N. Copeland,et al.  A novel cytokine‐inducible gene CIS encodes an SH2‐containing protein that binds to tyrosine‐phosphorylated interleukin 3 and erythropoietin receptors. , 1995, The EMBO journal.

[9]  Ursula Klingmüller,et al.  Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals , 1995, Cell.

[10]  O. Silvennoinen,et al.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin , 1993, Cell.

[11]  A. de la Chapelle,et al.  Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Chapelle,et al.  Familial erythrocytosis genetically linked to erythropoietin receptor gene , 1993, The Lancet.